Waverly Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Waverly Advisors LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,320 shares of the medical device company's stock, valued at approximately $258,000.

Several other large investors also recently added to or reduced their stakes in the company. Worldquant Millennium Advisors LLC purchased a new stake in DexCom in the 4th quarter worth about $32,262,000. Woodline Partners LP purchased a new stake in DexCom in the 4th quarter worth about $63,338,000. Waters Parkerson & CO. LLC increased its holdings in DexCom by 1.4% in the 4th quarter. Waters Parkerson & CO. LLC now owns 313,197 shares of the medical device company's stock worth $24,357,000 after acquiring an additional 4,364 shares during the last quarter. Triglav Skladi D.O.O. purchased a new stake in DexCom in the 4th quarter worth about $1,439,000. Finally, Twinbeech Capital LP increased its holdings in DexCom by 742.1% in the 4th quarter. Twinbeech Capital LP now owns 529,151 shares of the medical device company's stock worth $41,152,000 after acquiring an additional 466,312 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Price Performance

NASDAQ:DXCM traded up $1.65 during mid-day trading on Wednesday, reaching $86.98. The stock had a trading volume of 2,859,842 shares, compared to its average volume of 4,367,029. The firm has a 50 day moving average price of $73.97 and a two-hundred day moving average price of $78.41. The stock has a market capitalization of $34.11 billion, a P/E ratio of 60.83, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $128.63. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now owns 109,621 shares of the company's stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 83,110 shares of company stock worth $6,103,505. 0.32% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent analyst reports. Robert W. Baird reduced their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Piper Sandler reduced their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Finally, Canaccord Genuity Group lifted their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $98.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.